Investors Face September Deadline in Park Ha Biological Technology Lawsuit

The litigation alleges that Park Ha executives issued materially misleading statements regarding the firm's business operations and stock trading activity throughout the designated class period. According to the complaint, the company failed to disclose that it was the target of a fraudulent stock promotion scheme involving social media misinformation and impersonated financial professionals. Furthermore, the suit claims the company’s IPO was structured with an intentionally low public float to facilitate market manipulation, leaving investors unaware of the artificial forces driving the stock price.

Investors wishing to join the action can participate through a contingency fee arrangement, meaning no out-of-pocket costs are required. While the court has not yet certified a class, those who purchased shares during the class period may seek compensation. Interested parties are encouraged to contact Phillip Kim at the Rosen Law Firm to review their options or to move the court for lead plaintiff status before the late September cutoff.